|
|
|
|
|
05.06.26 - 14:03
|
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 21 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURITM (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline....
|
|
|
|
|
|
|
|
|
|
|
|
|
28.05.26 - 14:54
|
Entera′s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation (GlobeNewswire EN)
|
|
|
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera's single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
